1 Apr 2019 16:10
April 1, 2019
Verseon Corporation
("Verseon" or the "Company")
New TIDM and ISIN for Subscription Shares
FREMONT, Calif.-Verseon, a clinical-stage pharmaceutical company developing disruptive life-science technologies to advance global health, today announces that the Subscription Shares announced on March 19, 2019 will trade under a separate and new TIDM, 'VER2'. The Subscription Shares will also have a new ISIN, USU9221J1171, and SEDOL Code, BJ21MV8. Due to US securities laws, the Subscription Shares that will trade under VER2 are Regulation S restricted for a period of twelve months.
Verseon's existing common shares will remain unchanged and continue to trade under the existing ticker, 'VERS', and existing ISIN and SEDOL.
About Verseon
Verseon Corporation (AIM:VERS) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational engines with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.
Find Verseon on Twitter and LinkedIn.
- Ends -
For further information, please contact:
Verseon Corporation | www.verseon.com |
Sebastian Wykeham / Tina Schlafly | +1 (510) 225 9000 |
Arden Partners (NOMAD and Joint Broker) | |
Ruari McGirr / Ciaran Walsh / Alex Penney | +44 (0) 20 7614 5900 |
Cantor Fitzgerald Europe (Joint Broker) | |
Phil Davies | +44 (0) 20 7894 7000 |
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers) | |
Henry Harrison-Topham / Jamie Hooper | +44 (0) 20 7466 5000 |
For trade and pharma media enquiries, please contact
Vane Percy & Roberts | |
Simon Vane Percy | +44 (0) 1737 821 890 |